Genedrive successful in PHE National Framework Agreement for Diagnostics Goods and Services
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces it has been successful with its tender into Public Health England (“PHE”) under Lot 1 of the National Microbiology Framework (Diagnostic Goods and Services).
The PHE tender was opened in November 2020 and sought to appoint suppliers to a multi-lot national microbiology framework agreement relating to the supply of Diagnostics Goods and Services and covering Clinical Laboratory Diagnostic Testing Services.
The award of a framework contract is not exclusive to the Company, nor a guarantee of orders, however it does allow participating authorities to issue call-off orders for products in the future. All of genedrive’s currently available and CE marked products fall within the framework agreement: Genedrive®96 SARS-CoV-2 Kit, Genedrive®HCV ID Kit, Genedrive®MT-RNR1 ID Kit
David Budd, CEO of genedrive plc, said: “We are very pleased to have received notice of this contract award decision and look forward to the opportunity to engage with PHE and relevant authorities on future potential contracts. This is an early notification of the decision and we will update shareholders when we have more information on what this contract may mean for orders and revenues”.
About genedrive plc ( http://www.genedriveplc.com )
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The Company recently released a high throughput SARS-CoV-2 assay and has in development a Genedrive® Point of Care version of the assay, both based on Genedrive® chemistry.
If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates.
Terms of Website Use
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned